Investors

Emmaus Medical, a wholly-owned subsidiary of Emmaus Life Sciences, is engaged in the discovery, development, and commercialization of innovative and cost-effective treatments and therapies for rare diseases. Currently, the primary focus of our business is the late-stage development -- presently in Phase III clinical trials with the FDA – of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease.

We are also engaged, to a lesser extent, in the marketing and sale of NutreStore® [L-glutamine powder for oral solution] as a treatment for short bowel syndrome.

Over time, we plan to expand our business to include developing and marketing products to treat more common diseases.

SEC FILINGS

To access our filings with the U.S. Securities and Exchange Commission, please click here

Filings can be located under EMMAUS LIFE SCIENCES, INC. CIK#: 0001420031